The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Efficacy and Tolerability of Curmune Formulation in the Management of COVID-19: A Randomised Comparative Clinical Study


Affiliations
1 Director, Particle Life Sciences Pvt. Ltd., Mumbai, Maharashtra, India
2 Chest Physician, Vakratund Hospital, Nashik, Maharashtra, India
3 Department, of Research, Vakratund Hospital, Nashik, Maharashtra, India
     

   Subscribe/Renew Journal


Background: COVID-19 outbreak is a global threat, with lack of vaccines and antiviral medicine exaggerating the issue further. The Centers for Disease Control and Prevention recommend maintenance of personal hygiene as a modality to reduce chances of infection. Yet, another way is by improving the immunity. Viral infections are depended on body’s natural defences. Authors of current paper have studied the formulation containing proprietary blend of natural ingredients viz. Curcumin, Vitamin C, and Zinc based on their individual reported activities against SARS-CoV-2’s peptide.

Objective: To evaluate role of Curmune Tablets in the management of SARS-CoV-2 Infection (COVID-19) and its tolerability in comparison with standard treatment protocol designed by Ministry of Health and Family Welfare (MOHFW).

Study Design: In a randomized study, 100 patients tested positive for COVID-19 were enrolled during the month of September to December 2020 from Vakratund Hospital, Nashik, Maharashtra, India. The enrolled patients were administered either Curmune Tablets twice daily or given standard treatment protocol designed by MOHFW for 10 days. The patients were evaluated for decrease in axillary temperature; SpO2 and VAS score for cough and respiratory distress along with evaluating markers such as Interleukin-6, D-dimer, Ferritin and C Reactive Protein.

Results: In the Curmune group, within two to three days, temperature reduced considerably to afebrile level in all the subjects and remained afebrile till end of study. While in the standard treatment group, temperature reduced to afebrile stage in all the subjects by 4 days and thereafter remained afebrile till the end of study. The elevated levels of serum Interleukin-6, Di-dimer, Ferritin and C-Reactive Protein at baseline dropped considerably within normal limits within 10 days in the Curmune group in comparison to standard treatment group.

Conclusion: Curmune has shown for the first time to be useful in management of COVID-19 positive patients along with improvement in the immunity, within 48 to 36 hours of starting treatment. Curmune Tablets were well tolerated without any side effects in any of the patients treated, throughout the study duration.

Registration: CTRI/2020/09/027938.


Keywords

Curcumin, Vitamin C, Zinc, COVID-19, Immunity.
Subscription Login to verify subscription
User
Notifications
Font Size


  • World Health Organization [Internet]. COVID-19: Occupational health and safety for health workers. Interim Guidance. 2021 Feb 2. Available from: https://www.who.int/publications-detail/coronavirus-disease-(covid-19)-out break-rights-roles-and-responsibilities-of-health-workers-including key-considerations-for-occupational-safety-andhealth.

  • World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 –11 March 2020. 2020 March 11.

  • Ministry of Health and Family Welfare [Internet]. Information Regarding COVID-19 Vaccine. Available from: https://www.mohfw.gov.in/covid_vaccination/vaccination/index.html

  • Lin LT, Hsu WC, Lin CC. Antiviral natural products and herbal medicines. J Tradit Complement Med. 2014 Jan;4(1):24 35.

  • Kumar S, Dobos GJ, Rampp T. The Significance of Ayurvedic Medicinal Plants. J Evid Based Complementary Altern Med. 2017 Jul;22(3):494-501.

  • Huang F, Li Y, Leung EL, Liu X, Liu K, Wang Q, Lan Y, Li X, Yu H, Cui L, Luo H, Luo L. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacol Res. 2020 Aug;158:104929.

  • Wen CC, Kuo YH, Jan JT, Liang PH, Wang SY, Liu HG, Lee CK, Chang ST, Kuo CJ, Lee SS, Hou CC, Hsiao PW, Chien SC, Shyur LF, Yang NS. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007 Aug 23;50(17):4087-95.

  • Chen L, Hu C, Hood M, Zhang X, Zhang L, Kan J, Du J. A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis. Nutrients. 2020 Apr 24;12(4):1193.

  • Dound YA, Chaudhary S, Chaudhary SS and Dound BA. Plant Based Molecules for the Management of Covid-19. J Infect Dis Ther 2020. S2: 008.

  • World Health Organization [Internet]. WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. 2020 Feb 18; Geneva, Switzerland. Available from: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_ Final_18022020.pdf

  • Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood. 1999 Mar 15;93(6):1798-808.

  • Dofferhoff ASM, Piscaer I, Schurgers LJ, Visser MPJ, van den Ouweland JMW, de Jong PA, Gosens R, Hackeng TM, van Daal H, Lux P, Maassen C, Karssemeijer EGA, Vermeer C, Wouters EFM, Kistemaker LEM, Walk J, Janssen R. Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19. Clin Infect Dis. 2020 Aug 27:ciaa1258.

  • Miller JM, Thompson JK, MacPherson MB, Beuschel SL, Westbom CM, Sayan M, Shukla A. Curcumin: a double hit on malignant mesothelioma. Cancer Prev Res (Phila). 2014 Mar;7(3):330-40.

  • Dound YA, Chaudhary S, Chaudhary SS, Ahmad MM, Geesi MH, Alam P. Preventive Strategies for Management of COVID-19 Using Natural Molecules. Research Square; 2020.

  • Hemilä H. Vitamin C and SARS coronavirus. J Antimicrob Chemother. 2003 Dec;52(6):1049-50.

  • Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020 May;92(5):479-490.

  • Marreiro DD, Cruz KJ, Morais JB, Beserra JB, Severo JS, de Oliveira AR. Zinc and Oxidative Stress: Current Mechanisms. Antioxidants (Basel). 2017 Mar 29;6(2):24.

  • Maywald M, Wessels I, Rink L. Zinc Signals and Immunity. Int J Mol Sci. 2017 Oct 24;18(10):2222.

  • Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The Role of Zinc in Antiviral Immunity. Adv Nutr. 2019 Jul 1;10(4):696 710.

  • Gong J, Dong H, Xia QS, Huang ZY, Wang DK, Zhao Y, Liu WH, Tu SH, Zhang MM, Wang Q, Lu FE. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study. BMC Infect Dis. 2020 Dec 21;20(1):963.

  • Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020 Jun;127:104370.

  • Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034.

  • Bilgir O, Bilgir F, Calan M, Calan OG, Yuksel A. Comparison of pre- and post-levothyroxine high-sensitivity c-reactive protein and fetuin-a levels in subclinical hypothyroidism. Clinics (Sao Paulo). 2015 Feb;70(2):97-101.

  • Chalmers S, Khawaja A, Wieruszewski PM, Gajic O, Odeyemi Y. Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers. World J Crit Care Med. 2019 Sep 11;8(5):59-71.

  • Linkins LA, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly. Int J Lab Hematol. 2017 May;39 Suppl 1:98-103.

  • Paliogiannis P, Mangoni AA, Dettori P, Nasrallah GK, Pintus G, Zinellu A. D-Dimer Concentrations and COVID-19 Severity: A Systematic Review and Meta-Analysis. Front Public Health. 2020 Aug 4;8:432.


Abstract Views: 277

PDF Views: 4




  • Efficacy and Tolerability of Curmune Formulation in the Management of COVID-19: A Randomised Comparative Clinical Study

Abstract Views: 277  |  PDF Views: 4

Authors

Dound Yogesh
Director, Particle Life Sciences Pvt. Ltd., Mumbai, Maharashtra, India
Mandlik Sagar
Chest Physician, Vakratund Hospital, Nashik, Maharashtra, India
Suryavanshi Shrikant
Department, of Research, Vakratund Hospital, Nashik, Maharashtra, India
Dound Bhushan
Director, Particle Life Sciences Pvt. Ltd., Mumbai, Maharashtra, India

Abstract


Background: COVID-19 outbreak is a global threat, with lack of vaccines and antiviral medicine exaggerating the issue further. The Centers for Disease Control and Prevention recommend maintenance of personal hygiene as a modality to reduce chances of infection. Yet, another way is by improving the immunity. Viral infections are depended on body’s natural defences. Authors of current paper have studied the formulation containing proprietary blend of natural ingredients viz. Curcumin, Vitamin C, and Zinc based on their individual reported activities against SARS-CoV-2’s peptide.

Objective: To evaluate role of Curmune Tablets in the management of SARS-CoV-2 Infection (COVID-19) and its tolerability in comparison with standard treatment protocol designed by Ministry of Health and Family Welfare (MOHFW).

Study Design: In a randomized study, 100 patients tested positive for COVID-19 were enrolled during the month of September to December 2020 from Vakratund Hospital, Nashik, Maharashtra, India. The enrolled patients were administered either Curmune Tablets twice daily or given standard treatment protocol designed by MOHFW for 10 days. The patients were evaluated for decrease in axillary temperature; SpO2 and VAS score for cough and respiratory distress along with evaluating markers such as Interleukin-6, D-dimer, Ferritin and C Reactive Protein.

Results: In the Curmune group, within two to three days, temperature reduced considerably to afebrile level in all the subjects and remained afebrile till end of study. While in the standard treatment group, temperature reduced to afebrile stage in all the subjects by 4 days and thereafter remained afebrile till the end of study. The elevated levels of serum Interleukin-6, Di-dimer, Ferritin and C-Reactive Protein at baseline dropped considerably within normal limits within 10 days in the Curmune group in comparison to standard treatment group.

Conclusion: Curmune has shown for the first time to be useful in management of COVID-19 positive patients along with improvement in the immunity, within 48 to 36 hours of starting treatment. Curmune Tablets were well tolerated without any side effects in any of the patients treated, throughout the study duration.

Registration: CTRI/2020/09/027938.


Keywords


Curcumin, Vitamin C, Zinc, COVID-19, Immunity.

References